antifibrinolytic


Also found in: Encyclopedia, Wikipedia.

antifibrinolytic

 [an″te-, an″ti-fi″brĭ-no-lit´ik]
1. inhibiting fibrinolysis.
2. a substance that prevents fibrinolysis.

an·ti·fi·bri·no·lyt·ic

(an'tē-fī-brin'ō-lit'ik),
Denoting a substance that decreases the breakdown of fibrin (for example, aminocaproate.

antifibrinolytic

/an·ti·fi·bri·no·lyt·ic/ (-fi″brĭ-no-lit´ik) inhibiting or preventing fibrinolysis, or an agent that does this.

an·ti·fi·bri·no·lyt·ic

(an'tē-fī-brin-ō-lit'ik)
Denoting a substance that decreases the breakdown of fibrin (e.g., aminocaproic acid).

antifibrinolytic

inhibiting fibrinolysis.
References in periodicals archive ?
In comparison to the alternatives, antifibrinolytic therapy is inexpensive and simple to administer.
These activators (profibrinolytic drivers) are opposed by antiactivators such as tPA inhibitors [mainly plasminogen activator inhibitor (PAI)], plasmin inhibitor (PI), and thrombin-activatable fibrinolysis inhibitor (TAFI), which act as antifibrinolytic drivers.
Last, by comparing the base extrinsic test to another modified extrinsic test which adds an antifibrinolytic agent, hyperfibrinolysis can be confirmed, and a patient's response to antifibrinolytic therapy can be demonstrated.
As an antifibrinolytic agent tranexamic acid which is especially inexpensive and efficient is very useful in stopping short-term hemorrhages in the form of leakage.
The literature describes various dental treatment protocols that result in a remarkable reduction in the number of bleeding episodes following oral procedures, including the use of oral antifibrinolytic agents, systemic hemostatic replacement therapy, and use of local hemostatic agents (12), (13).
There may also be benefit in the simultaneous use of an antifibrinolytic agent such as cyclokapron.
The recommendation took into account a full review of the benefits and risks of all antifibrinolytic medicines, which found that the results of the study on which the suspension of aprotinin was based were unreliable.
There is no experience with antifibrinolytic agents (tranexamic acid, aminocaproic acid) in individuals receiving rivaroxaban.
Use of invasive monitoring, cell salvage and antifibrinolytic drugs.
Red blood cell (RBC) transfusions (for symptomatic anaemia), platelet transfusions (for severe thrombocytopenia or thrombocytopenic bleeding), antibiotics and antifibrinolytic agents are all frequently used as part of supportive care.
Approximately 57% of patients reported use of attenuated androgens, antifibrinolytic agents, or C1 inhibitors.